期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
药物蛋白质组学研究进展 被引量:4
1
作者 蒋宁 周文霞 张永祥 《中国新药杂志》 CAS CSCD 北大核心 2005年第12期1391-1394,共4页
药物蛋白质组学是基因组和药物发现之间的桥梁,目前已广泛应用于临床和生物医学的各个领域。其研究内容在临床前包括:构建分子药理筛选模型、筛选药物作用靶点、研究药物作用机制和毒理机制等;临床研究包括:利用疾病特异性蛋白质作为疾... 药物蛋白质组学是基因组和药物发现之间的桥梁,目前已广泛应用于临床和生物医学的各个领域。其研究内容在临床前包括:构建分子药理筛选模型、筛选药物作用靶点、研究药物作用机制和毒理机制等;临床研究包括:利用疾病特异性蛋白质作为疾病分类分型和诊断的标志,还用于评价疗效和预测疾病的预后和转归等。 展开更多
关键词 药物蛋白质组学 分子药理筛选模型 药物作用靶点 药物作用机制 毒理机制
下载PDF
Group Ⅱ p21-activated kinases as therapeutic targets in gastrointestinal cancer 被引量:2
2
作者 Yang-Guang Shao Ke Ning Feng Li 《World Journal of Gastroenterology》 SCIE CAS 2016年第3期1224-1235,共12页
P21-activated kinases(PAKs) are central players in various oncogenic signaling pathways. The six PAK family members are classified into group Ⅰ(PAK1-3) and group Ⅱ(PAK4-6). Focus is currently shifting from group Ⅰ ... P21-activated kinases(PAKs) are central players in various oncogenic signaling pathways. The six PAK family members are classified into group Ⅰ(PAK1-3) and group Ⅱ(PAK4-6). Focus is currently shifting from group Ⅰ PAKs to group Ⅱ PAKs. Group Ⅱ PAKs play important roles in many fundamental cellular processes, some of which have particular significance in the development and progression of cancer. Because of their important functions, group Ⅱ PAKs have become popular potential drug target candidates. However, few group Ⅱ PAKs inhibitors have been reported, and most do not exhibit satisfactory kinase selectivity and "drug-like" properties. Isoform- and kinase-selective PAK inhibitors remain to be developed. This review describes the biological activities of group Ⅱ PAKs, the importance of group Ⅱ PAKs in the development and progression of gastrointestinal cancer, and smallmolecule inhibitors of group Ⅱ PAKs for the treatment of cancer. 展开更多
关键词 GROUP p21-activated KINASES SIGNALINGPATHWAY GASTROINTESTINAL cancer PAK4 INHIBITOR drugtarget
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部